已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

FAP-targeted radioligand therapy with 68Ga/177Lu-DOTA-2P(FAPI)2 enhance immunogenicity and synergize with PD-L1 inhibitors for improved antitumor efficacy

免疫原性 放射性配体 多塔 靶向治疗 医学 药理学 放射化学 癌症研究 化学 内科学 癌症 免疫学 受体 抗体 螯合作用 有机化学
作者
Jian‐Hao Chen,Yangfan Zhou,Yizhen Pang,Kaili Fu,Qicong Luo,Long Sun,Hua Wu,Qin Lin,Guoqiang Su,Xiaoyuan Chen,Liang Zhao,Haojun Chen
出处
期刊:Journal for ImmunoTherapy of Cancer [BMJ]
卷期号:13 (1): e010212-e010212 被引量:25
标识
DOI:10.1136/jitc-2024-010212
摘要

Background Fibroblast activation protein (FAP)-targeted radioligand therapy, with immunomodulatory effects, has shown efficacy in both preclinical and clinical studies. We recently reported on a novel dimeric FAP-targeting radiopharmaceutical, 68 Ga/ 177 Lu-DOTA-2P(FAPI) 2 , which demonstrated increased tumor uptake and prolonged retention in various cancers. However, further exploration is required to understand the therapeutic efficacy and underlying mechanisms of combining 68 Ga/ 177 Lu-DOTA-2P(FAPI) 2 radioligand therapy with PD-1/PD-L1 immunotherapy. Methods Regarding the change in PD-L1 expression and DNA double-strand breaks induced by radiopharmaceuticals, CT26-FAP tumor cells were incubated with 68 Ga and 177 Lu labeled DOTA-2P(FAPI) 2 , respectively. Monotherapy with 68 Ga-DOTA-2P(FAPI) 2 , 177 Lu-DOTA-2P(FAPI) 2 , and PD-L1 immunotherapy as well as combination therapy ( 68 Ga/ 177 Lu-DOTA-2P(FAPI) 2 and PD-L1 immunotherapy) were tested and evaluated to evaluate in vivo antitumor efficacy. Furthermore, immunohistochemical staining and single-cell RNA sequencing were used to analyze changes in the tumor microenvironment (TME) and elucidate the underlying mechanisms of action of this combination therapy. Results Our findings indicated that FAP-targeting radiopharmaceuticals can induce DNA double-strand breaks and upregulate PD-L1 expression, with 177 Lu-DOTA-2P(FAPI) 2 proving to be more effective than 68 Ga-DOTA-2P(FAPI) 2 . Both 68 Ga-DOTA-2P(FAPI) 2 and 177 Lu-DOTA-2P(FAPI) 2 radiopharmaceuticals significantly improved therapeutic outcomes when combined with anti-PD-L1 monoclonal antibody (αPD-L1 mAb). Notably, the combination of 177 Lu-DOTA-2P(FAPI) 2 with αPD-L1 mAb immunotherapy eliminated tumors in mouse models. Mice treated with this regimen not only exhibited exceptional responses to the initial immune checkpoint inhibitor therapy but also showed 100% tumor rejection on subsequent tumor cell re-inoculation. Further mechanistic studies have shown that 177 Lu-DOTA-2P(FAPI) 2 combined with αPD-L1 mAb can reprogram the TME, enhancing antitumor intercellular communication, which activates antitumor-related intercellular contacts such as FasL-Fas interactions between T cells and NK cells with tumor cells and increasing the proportion of infiltrating CD8+ T-cells while reducing regulatory T cells and inhibiting tumor progression. Our research also demonstrates that mature neutrophils play a role in enhancing the efficacy of the combined therapy, as shown in neutrophil-blocking experiments. Conclusions Our study robustly advocates for use of FAP-targeting radiopharmaceuticals, particularly 177 Lu-DOTA-2P(FAPI) 2 , alongside immunotherapy in treating FAP-positive tumors. This combination therapy transforms the TME and enables a translatable approach to increasing the sensitivity to PD-1/PD-L1 immunotherapy, leading to improved complete remission rates and extended overall survival.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Rain完成签到 ,获得积分10
刚刚
2秒前
我是老大的应助被刻苦乐天采纳,获得10
3秒前
3秒前
忧郁芷烟发布了新的文献求助10
4秒前
FashionBoy的应助被隐形的晓灵采纳,获得10
4秒前
5秒前
华仔的应助被狗熊岭在逃翠花采纳,获得10
5秒前
冷酷惠完成签到 ,获得积分10
5秒前
5秒前
小二郎的应助被三花大户采纳,获得10
8秒前
余叶发布了新的文献求助10
8秒前
科学心完成签到,获得积分10
9秒前
isabella完成签到,获得积分10
9秒前
9秒前
任性雁露发布了新的文献求助10
10秒前
10秒前
不易发布了新的文献求助10
10秒前
下北沢之兽完成签到 ,获得积分10
12秒前
CipherSage的应助被DW采纳,获得10
12秒前
李健完成签到,获得积分10
14秒前
hsj完成签到,获得积分10
15秒前
16秒前
16秒前
16秒前
Hunter完成签到,获得积分10
17秒前
17秒前
18秒前
三花大户发布了新的文献求助10
20秒前
K2C完成签到,获得积分10
21秒前
正直雪柳完成签到,获得积分20
21秒前
刻苦乐天发布了新的文献求助10
22秒前
姜OMG发布了新的文献求助10
22秒前
光亮的成败完成签到,获得积分10
22秒前
紫菜珍藏版完成签到 ,获得积分10
23秒前
科研通AI65的应助被DW采纳,获得10
24秒前
27秒前
姜OMG完成签到,获得积分10
28秒前
妖九笙完成签到 ,获得积分10
28秒前
imcwj完成签到 ,获得积分10
30秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184889
求助须知:如何正确求助?哪些是违规求助? 9573836
关于积分的说明 21833242
捐赠科研通 7782263
什么是DOI,文献DOI怎么找? 3434429
关于科研通互助平台的介绍 2558581
邀请新用户注册赠送积分活动 2481082